繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

周日报道,REGENX比奥强调2026年催化剂,因为RGX-202显示出持久的18个月功能益处,预计FDA PDUFA、BLA备案和多个百分比读数

2026-01-12 16:17

  • New Phase I/II RGX-202 functional data demonstrates long-term, durable treatment effect at pivotal dose at 18 months 
  • Robust patient enrollment in confirmatory trial continues, expect majority of patients to be dosed by planned BLA filing, mid-year
  • Expecting FDA PDUFA decision and multiple pivotal top-line data readouts in 2026 to support potential commercial launches 2026-2028
  • In-house manufacturing and strategic global partnerships driving commercial readiness
  • Presentation at 44th Annual J.P. Morgan Healthcare Conference Wednesday, January 14

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。